Megakaryocyte growth factors

Megakaryocyte growth factors

Mechanism of action

INTERLEUKIN 11 (the recombinant form is called OPRELVEKIN) and THROMBOPOIETIN increase platelet production

autoantibodies form after infusion of recombinant forms of THROMBOPOIETIN

ROMIPLOSTIM is a nonimmunogenic peptide agonist of the thrombopoietin receptor (Mpl)
- it is the first approved "peptibody"
- two Mpl-binding peptides were linked to human F_c fragments

Pharmacokinetics

ROMIPLOSTIM has a half-life of 3-4 days
- longer t_1/2 in patients with thrombocytopenia; shorter in patients whose platelet counts have recovered

Therapeutic Uses

thrombocytopenia, particularly following chemotherapy
- idiopathic thrombocytopenia (ITP)

Side effects

INTERLEUKIN 11

LIFE-THREATENING:

	SERIOUS	INNOCUOUS
COMMON	atrial fibrillation (especially in the elderly or children)	fatigue headache dizziness mild/moderate edema dyspnea (due to fluid in lungs) anemia (due to hemodilution)
RARE	hypokalemia
doesn't cause fever (unlike many other cytokines)

ROMIPLOSTIM

well tolerated except for mild headache on the day of administration

Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 27-apr-15 1:11 PM